EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pulmonary arterial hypertension: Sex matters

Joshua P Dignam, Smriti Sharma, Ioannis Stasinopoulos, Margaret R MacLean

British Journal of Pharmacology · 2024-04 · 181 (7) · 938-966

DOI: 10.1111/bph.16277 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 16.01.2024. Verfasst von Joshua P Dignam und 3 weiteren Autor:innen. Beteiligte Einrichtung: Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland, UK. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Hypertension, Pulmonary, Ventricular Dysfunction, Right. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 289 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary arterial hypertension (PAH) is a complex disease of multifactorial origin. While registries have demonstrated that women are more susceptible to the disease, females with PAH have superior right ventricle (RV) function and a better prognosis than their male counterparts, a phenomenon referred to as the ‘estrogen paradox’. Numerous pre‐clinical studies have investigated the involvement of sex hormones in PAH pathobiology, often with conflicting results. However, recent advances suggest that abnormal estrogen synthesis, metabolism and signalling underpin the sexual dimorphism of this disease. Other sex hormones, such as progesterone, testosterone and dehydroepiandrosterone may also play a role. Several non‐hormonal factor including sex chromosomes and epigenetics have also been implicated. Though the underlying pathophysiological mechanisms are complex, several compounds that modulate sex hormones levels and signalling are under investigation in PAH patients. Further elucidation of the estrogen paradox will set the stage for the identification of additional therapeutic targets for this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Arterial HypertensionHypertension, PulmonaryVentricular Dysfunction, RightHumansMaleFemaleGonadal Steroid HormonesEstrogensTestosterone

Stichwörter der Autor:innen

estrogenpulmonary hypertensionright ventriclesex chromosomessex hormones

Substanzen

Gonadal Steroid HormonesEstrogensTestosterone

Autor:innen und Institutionen

  • Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland, UK.
  • Mass Spectrometry Core, Edinburgh Clinical Research Facility, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, Scotland, UK.

Förderung

  • Medical Research Council
  • British Heart Foundation

Zitieren

APA

Dignam, J. P., Sharma, S., Stasinopoulos, I., & MacLean, M. R. (2024). Pulmonary arterial hypertension: Sex matters. British Journal of Pharmacology, 181(7), 938-966. https://doi.org/10.1111/bph.16277

Vancouver

Dignam JP, Sharma S, Stasinopoulos I, MacLean MR. Pulmonary arterial hypertension: Sex matters. British Journal of Pharmacology. 2024;181(7):938-966. doi:10.1111/bph.16277

BibTeX
@article{Dignam2024,
  author = {Dignam, Joshua P and Sharma, Smriti and Stasinopoulos, Ioannis and MacLean, Margaret R},
  title = {Pulmonary arterial hypertension: Sex matters},
  journal = {British Journal of Pharmacology},
  year = {2024},
  volume = {181},
  number = {7},
  pages = {938--966},
  doi = {10.1111/bph.16277}
}
Kostenlos starten →